CSPC PHARMA (01093) releases annual results with a net profit attributable to shareholders of 3.882 billion yuan, a decrease of 10.3% compared to the previous year. 5 external authorizations demonstrate innovative strength.

CSPC PHARMA (01093) released its annual performance report for the year ending December 31, 2025, with total revenue of 26.006 billion yuan, a decrease of 10.4% year-on-year; attributable profit to shareholders was 3.882 billion yuan, a decrease of 10.3% year-on-year; basic earnings per share were 33.98 cents; and final dividends were 15 Hong Kong cents. The group continues to enrich its product portfolio and enhance its product competitiveness. Several major products and new indications approved for listing in 2024-2025 have brought sustained growth momentum to the group: Mifule as an innovative drug in the field of cerebrovascular diseases, has continued and strengthened the group's advantage in this field, forming a synergistic effect with Enbipu, further consolidating the group's leading position in the treatment of cerebrovascular diseases; EnshuXing (Enlangsuvadantinib injection), the first omazolizumab monoclonal antibody biosimilar drug Enyitan, the diabetes drug Plulicitin tablets, and the successful listing of Meloxyconna crystal injection and other products have promoted a more balanced layout for the group in the areas of autoimmune diseases, endocrine metabolism, and anti-tumor treatments, significantly enhancing future growth space. The group has always believed that research and development innovation is the core competitiveness of pharmaceutical companies and the key to solving "bottlenecks" and driving high-quality development of the industry. In 2025, against the background of continuous empowerment of industry innovation policies, the group continues to increase research and development investment, rely on eight major innovative research and development platforms, adhere to a clinical needs-oriented approach, and systematically promote the research and development and clinical development of innovative drugs. In 2025, the group obtained 14 production permits, 73 clinical permits, and identified 5 breakthrough therapies, many of which are heavyweight products with global patents and high market value. The group continues to drive innovation pipeline to land, strengthen key core technology breakthroughs, rely on two national key laboratories, focus on applied basic research and breakthroughs in common technical problems, actively explore cutting-edge technologies such as cell therapy and nucleic acid therapy, and promote the research and development of products such as autologous CAR-T candidate drug SYS6055, tumor therapeutic vaccines, small nucleic acid drugs to further improve the innovative product layout, demonstrating the strong innovative research and development capabilities of the group. In terms of digitalization, the group actively deepens the application of AI technology in drug development, expands AI-assisted research and development platforms, uses technology to empower innovation, accelerates intelligent transformation, and continues to improve research and development efficiency and outcome transformation capabilities. In terms of internationalization, the group steadily promotes its internationalization strategy, accelerates overseas market layout, and focuses on promoting high-end complex injection preparations, single/dual antibody biological preparations, and inhalers in European and American markets. In addition, the group actively promotes the listing of liposomal amphotericin B injections in the United States and the European Union to break through overseas high-end market barriers. At the same time, the group continues to deepen its presence in Belt and Road countries, advancing product registration and sales in countries such as Singapore, Thailand, Russia, and Vietnam, establishing deep cooperation with local strategic customers, promoting the construction of Southeast Asian academic promotion platforms, and continuously enhancing the contribution of overseas business. In terms of business expansion, since the beginning of 2025, the group has completed 5 outbound authorizations with a total contract amount of $28.21 billion, fully demonstrating the group's international innovation capabilities and technological strength, significantly enhancing the group's international reputation and industry influence, and laying a solid foundation for expanding overseas markets and deepening international cooperation.